Figure 5.

Survival curves (5-year) of patients with PDAC with miR-1 and miR-214 ISH status. (A) Patients with PDAC who were negative for miR-1, as determined by ISH, demonstrated significantly poorer 5-year survival compared with those with positive ISH results (*P<0.05 vs. miR-1 positive samples). (B) Patients with miR-214-positive ISH signaling exhibited significantly poorer survival compared with those with negative ISH signaling (*P<0.05 vs. miR-214 negative samples). ISH, in situ hybridization; miR, microRNA; PDAC, pancreatic ductal adenocarcinoma.